85 related articles for article (PubMed ID: 10163540)
1. Comparative clinical studies of platelet concentrates: effects on clinical outcome and the use of healthcare resources. NBS Platelet Study Group.
Pamphilon DH
Transfus Sci; 1996 Sep; 17(3):343-6. PubMed ID: 10163540
[TBL] [Abstract][Full Text] [Related]
2. Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions.
Pruss A; Kalus U; Radtke H; Koscielny J; Baumann-Baretti B; Balzer D; Dörner T; Salama A; Kiesewetter H
Transfus Apher Sci; 2004 Feb; 30(1):41-6. PubMed ID: 14746820
[TBL] [Abstract][Full Text] [Related]
3. Use of random versus apheresis platelet concentrates.
Andreu G; Vasse J; Sandid I; Tardivel R; Semana G
Transfus Clin Biol; 2007 Dec; 14(6):514-21. PubMed ID: 18417401
[TBL] [Abstract][Full Text] [Related]
4. Platelet transfusion therapy.
Slichter SJ
Hematol Oncol Clin North Am; 2007 Aug; 21(4):697-729, vii. PubMed ID: 17666286
[TBL] [Abstract][Full Text] [Related]
5. The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non-selected haematological population of patients.
Levin MD; van der Holt B; de Veld JC; Gratama JW; de Vries W; van't Veer MB
Vox Sang; 2004 Nov; 87(4):291-8. PubMed ID: 15585026
[TBL] [Abstract][Full Text] [Related]
6. A critical comparison of platelet preparation methods.
Vassallo RR; Murphy S
Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
[TBL] [Abstract][Full Text] [Related]
7. Background, rationale, and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients.
Slichter SJ
J Clin Apher; 2006 Apr; 21(1):78-84. PubMed ID: 16619231
[TBL] [Abstract][Full Text] [Related]
8. The use of PEG-rhuMGDF in platelet apheresis.
Kuter DJ
Stem Cells; 1998; 16 Suppl 2():231-42. PubMed ID: 11012195
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized study of three types of platelet concentrates in patients with haematological malignancy: corrected platelet count increments and frequency of nonhaemolytic febrile transfusion reactions.
Anderson NA; Gray S; Copplestone JA; Chan DC; Hamon M; Prentice AG; Johnson SA; Phillips M; van Waeg G; Oakhill A; Abeyasekera S; Pamphilon DH
Transfus Med; 1997 Mar; 7(1):33-9. PubMed ID: 9089983
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.
Gurkan E; Patah PA; Saliba RM; Ramos CA; Anderson BS; Champlin R; de Lima M; Lichtiger B
Bone Marrow Transplant; 2007 Sep; 40(5):461-4. PubMed ID: 17589530
[TBL] [Abstract][Full Text] [Related]
11. Effects of prestorage vs poststorage leukoreduction on the rate of febrile nonhemolytic transfusion reactions to platelets.
Wang RR; Triulzi DJ; Qu L
Am J Clin Pathol; 2012 Aug; 138(2):255-9. PubMed ID: 22904138
[TBL] [Abstract][Full Text] [Related]
12. [Risk Assessment of Single-Donor (Apheresis) Platelet Concentrates and Pooled Whole-Blood-Derived Platelet Concentrates].
Hitzler W; Hutschenreuter G; Wartensleben H;
Clin Lab; 2015; 61(7):869-75. PubMed ID: 26299092
[TBL] [Abstract][Full Text] [Related]
13. [Introduction of platelet additive solution in platelet concentrates: towards a decrease of blood transfusion reactions].
Rebibo D; Simonet M; Hauser L
Transfus Clin Biol; 2008 Nov; 15(5):289-93. PubMed ID: 18930424
[TBL] [Abstract][Full Text] [Related]
14. Vincristine-laden platelet transfusion for patients with refractory thrombocytopenia.
Ganti AK; Landmark JD; Kessinger A; Smith LM; Tarantolo SR
In Vivo; 2006; 20(4):559-63. PubMed ID: 16900790
[TBL] [Abstract][Full Text] [Related]
15. Analysis of transfusion reactions associated with prestorage-pooled platelet components.
Tormey CA; Sweeney JD; Champion MH; Pisciotto PT; Snyder EL; Wu Y
Transfusion; 2009 Jun; 49(6):1242-7. PubMed ID: 19389029
[TBL] [Abstract][Full Text] [Related]
16. Markers of platelet activation and apoptosis in platelet concentrates collected by apheresis.
Procházková R; Andrýs C; Hubácková L; Krejsek J
Transfus Apher Sci; 2007 Oct; 37(2):115-23. PubMed ID: 17945536
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution.
van Rhenen DJ; Gulliksson H; Cazenave JP; Pamphilon D; Davis K; Flament J; Corash L
Transfus Med; 2004 Aug; 14(4):289-95. PubMed ID: 15285725
[TBL] [Abstract][Full Text] [Related]
18. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy.
Akkök CA; Brinch L; Lauritzsen GF; Solheim BG; Kjeldsen-Kragh J
Vox Sang; 2007 Jul; 93(1):42-8. PubMed ID: 17547564
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
[TBL] [Abstract][Full Text] [Related]
20. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment.
Osselaer JC; Messe N; Hervig T; Bueno J; Castro E; Espinosa A; Accorsi P; Junge K; Jacquet M; Flament J; Corash L
Transfusion; 2008 Jun; 48(6):1061-71. PubMed ID: 18346019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
